GlassScriptPhysician profile
Thomas Yun-Ki Kim
NPI 1194726844
$2,596.75
in general payments reported to CMS, 2019-2025
23 companies · $346 in 2025
The $346 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $181 · 2021: $271 · 2022: $669 · 2023: $309 · 2024: $337 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $991.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $575.28 | 2019-2025 | Cardiomems, Mitraclip |
| Boston Scientific Corporation | $257.25 | 2019-2022 | |
| Biotronik INC. | $256.33 | 2019 | |
| Medtronic, INC. | $219.54 | 2023-2025 | Symplicity G3, Resolute Onyx |
| Janssen Pharmaceuticals, INC | $179.33 | 2020-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $147.76 | 2022-2025 | Farxiga |
| Amarin Pharma, INC. | $125.83 | 2020-2021 | |
| Pfizer INC. | $108.08 | 2022-2025 | |
| Astellas Pharma US INC | $99.00 | 2021 | |
| Alnylam Pharmaceuticals INC. | $86.00 | 2022-2024 | Onpattro |
| Kestra Medical Technology Services, INC. | $85.43 | 2024 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $71.54 | 2019-2023 | Lifevest |
| Merck Sharp & Dohme LLC | $66.63 | 2022-2023 | Verquvo |
| Amgen INC. | $62.30 | 2021-2024 | Repatha |
| Abiomed | $59.07 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $42.04 | 2022 | |
| Esperion Therapeutics, INC. | $28.41 | 2021-2024 | Nexletol |
| Djo, LLC | $27.01 | 2024 | Donjoy |
| Kiniksa Pharmaceuticals, LTD. | $24.94 | 2023 | Arcalyst |
| Cvrx, INC. | $23.05 | 2025 | Barostim Neo System |
| Portola Pharmaceuticals, LLC | $18.94 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $17.15 | 2023 | Camzyos |
| Medtronic Vascular, INC. | $15.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.